SUMMARY In order to study the mode of action of beta-adrenoreceptor antagonists in essential tremor the efficacy of singe oral doses of 2, 4 and 10 mg LI 32-468, a peripherally acting, selective beta-2 adrenoreceptor antagonist, was compared with a single oral dose of 120 mg propranolol in a randomised, double blind, placebo controlled trial. Both the lowest dose of LI and propranolol were shown to be equally superior to placebo in attenuating tremor magnitude. This finding supports the contention that the beneficial effect of beta-adrenoreceptor antagonists in essential tremor is mediated via peripheral beta-2 receptor mechanisms.
Essential tremor is a common monosymptomatic disorder of unknown aetiology. Betaadrenoreceptor antagnoists are considered the drugs of first choice in its treatment. ' Whilst some of the behavioural characteristics of essential tremor resemble enhanced physiological tremor and it is now accepted that enhanced physiological tremor is mediated by peripheral beta-2 mechanisms,2 there is still dispute as to the site and mode of action of beta-adrenoreceptor antagonists in the control of essential tremor.
The drug which so far has been proved to be of greatest therapeutic benefit is propranolol,36 a non-selective beta-adrenoreceptor antagonist which, due to its lipid solubility, readily penetrates the central nervous system. A number of clinical trials support the contention that the main effect of these drugs is mediated predominantly by peripheral beta-2 adrenoreceptor mechanisms.78 However, intra-arterial and intra-venous studies with propranolol have implicated central effects of this drug9 and some studies have shown that the selective beta-1 adrenoreceptor antagonist metoprolol can also be effective in reducing tremor in some because at the dosages used the relative selectivity of beta-adrenoreceptor antagonists is at least partially lost, and as metoprolol is a lipid soluble drug, central and peripheral effects cannot be differentiated. In a recent study Leigh et al '6 compared the effects of atenolol, sotalol and metoprolol and found no support for the concept that central or peripheral beta-i mechanisms are important in essential tremor and that the beneficial effect of betaadrenoreceptor antagonists may be mediated predominantly through peripheral beta-2 adrenoreceptor mechanisms. However, from the results presented in that study atenolol, a hydrophilic, predominantly beta-1 selective adrenoreceptor antagonist, was equally effective in attenuating tremor as the non-selective adrenoreceptor antagonist sotalol on "objective" assessments. Therefore, in order to investigate further the mechanism of action of these drugs, a new agent with a highly selective effect on peripheral beta-2 adrenoreceptors is needed. LI 32-468 (4-(3-tert-butylamino-2-hydroxypropoxy)spiro[cyclohexan-1, 2-indan]-1-on hydrogen malonate) is a freely hydrophilic, selective beta-2 adrenoreceptor antagonist which in animal studies shows signs of effects on the central nervous system only at extremely high doses, for example, shown to be devoid of cardiac beta-adrenoceptor blocking activity (that is, a selective beta-2 receptor antagonist). '8 The order of treatment was randomised.
Tremor recordings and measurements of supine and standing pulse rates were repeated 2 hours after drug administration, when the plasma levels of both drugs were expected to be approaching maximum.
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Tremor analysis was performed on-line using a Hewlett Packard 5420A signal analyser.20 For each condition, that is, before and after treatment, the program averaged 150 auto-spectra each derived from overlapping 10-24 second samples of tremor. Fifty samples were taken from the beginning of each of the three separate recording periods and approximately 45 seconds of tremor recording contributed to the analysis in each period. The advantage of "overlap" analysis is that it compensates for the reduced contribution of the beginning and the end of the data sample which results from the application of a Hanning window. The spectra, averaged thus, were displayed for measurement in the form of "auto-spectra" in which the root mean square (rms) magnitude of the frequency components was plotted as a function of frequency. For simple characterisation of the tremor, measurements were taken of the frequency (Hz) of the dominant peak and of its amplitude scaled in rms acceleration, the unit of acceleration being taken as lg (g = 981 cm/s2). As There was a significant postive correlation between baseline magnitude of tremor and reduction in tremor magnitude for both propranolol and 2 mg LI (absolute change p < 0-01, percentage change p < 0.05). There was no significant correlation between reduction in tremor magnitude and age, duration of symptoms, and tremor frequency.
Pulse rate There was no significant difference in the pulse rate recorded after 1, 2, and 3 minutes of standing in each patient. The means of the three values was therefore taken for further calculations. Pre drug values of supine and standing pulse rate did not differ significantly between treatments.
Significant decreases in standing tachycardia were 3 . There was no correlation between drug levels and reduction in tremor magnitude.
Side effects
None of the patients complained of any adverse reactions after any of the doses of LI or propranolol.
Discussion
The present study clearly demonstrates that a single oral dose of 2 mg LI 32-468 is significantly better than placebo in reducing the magnitude of essential tremor. The mean reduction in tremor magnitude of 42% of baseline value was equipotent with the effect of 120 mg propranolol. Single doses of 4 mg and 10 mg LI did not have a significantly greater effect on tremor magnitude than placebo. The explanation for this is not clear. It is apparent from the results on the inhibition of standing tachycardia (fig 3) that at the 4 mg and 10 mg doses there has been some loss of beta-2 selectivity. This in itself would not explain loss of tremorlytic activity as pro- studies on normal human volunteers. '8 There has been much recent discussion as to the mode of action of beta-adrenoreceptor antagonists on essential tremor, in particular whether effects in the central nervous system are important and also whether there is significant effect via beta-1 mechanisms either peripheral or central. The present study does however provide support for the contention that the action of beta-adrenoreceptor antagonists on essential tremor is mediated predominantly by peripheral beta-2 adrenoreceptors. The effective dose of LI 32-468, that is 2 mg has no significant effects on beta-1 adrenoreceptors as evidenced by the lack of inhibition of standing tachycardia in the patients in this study and in normal volunteers. '8 It is a markedly hydrophilic compound and therefore has insignificant central effects, particularly when given as a single 2 mg dose in that central accumulation of the drug or an active metabolite could not have occurred. Membrane stabilising activity would not be an important factor in the tremorlytic effect of 2 mg LI as in the animal model the membrane stabilising activity of LI is weaker than that of propranolol'7 and even with propranolol it only becomes significant at plasma levels considerably greater than that which produces beta blockade and attenuation of tremor.2324 Furthermore it would be expected that if the membrane stabilising activity was important the higher doses of LI should have been at least equally effective. Thus, a single oral dose of 2 mg LI, a peripherally acting selective beta-2 adrenoreceptor antagonist was shown to be equipotent, in its effect on tremor magnitude, to 120 mg propranolol. This finding supports the contention of Leigh et al '6 that the beneficial effects of beta-adrenoreceptor antagonists are mediated predominantly via peripheral beta-2 adrenoreceptor mechanisms.
These peripheral beta-2 adrenoreceptors are located on the extrafusal muscle fibres2526 and on Beta-adrenoreceptor mechanisms in essential tremor: the intrafusal fibres of the muscle spindles.27-29 It has been demonstrated that sympathomimetric amines such as adrenaline will induce tremor or exaggerate essential tremor by a direct effect on these receptors producing both an alteration in muscle contractility25 26 and, more importantly, an increase in muscle spindle sensitivity,30 with resulting synchronisation of afferent feedback during the stretch phase of spindle discharge. Such agonist effects can readily be blocked by beta-2 adrenoreceptor antagonist activity at these receptor sites, though it has not been proved that these are necessarily the only peripheral sites of action of these drugs in essential tremor. 3' Since the beneficial effect of beta-adrenoreceptor antagonists on essential tremor is peripherally determined, it would be unlikely that complete attenuation of a centrally "driven" tremor could be achieved. Indeed, complete abolition of essential tremor by these drugs is rarely found clinically or in trials employing objective measurement techniques. '5 34 35 In contrast complete attenuation of large amplitude, low frequency (therefore centrally determined) essential tremor '9 can be seen using drugs (for example primidone) whose primary action is in the central nervous system.32
In the present study there was no correlation between either plasma LI or propranolol levels and reduction in tremor amplitude. This lack of correlation has been a consistent finding in studies of the effect of propranolol on essential tremor.3334 This may reflect marked inter-patient differences in the severity and responsiveness of tremor,'5 the degree of protein binding3" the presence of active metabolite(s) or that the drug levels achieved were above that in which any relationship between plasma level and response exists.
Single dose studies of the effects of betaadrenoreceptor antagonists in essential tremor do not always predict the effects of the drug when given on prolonged administration,35 therefore it is necessary to follow up these initial findings with a controlled study to determine whether the effect of the drug is maintained in chronic use. If the response of tremor to small doses of LI is maintained on prolonged administration then this drug may provide a useful addition to drugs currently available for the management of essential tremor. In situations where simultaneous beta-I and beta-2 antagonism may be disadvantageous to the patient with essential tremor, such as in the elderly or in patients with heart disease, there may be an indication to use LI in preference to propranolol. In other tremulous states such as drug withdrawal, or drug intoxication, there may also be a preference for a beta-2 adrenoreceptor antagonist. -ELong-term studies will be-necessary 981 to determine whether this drug is better tolerated in patients with essential tremor than propranolol.
